ACCESS Newswire

Cactus Life Sciences

Share
nspm and eluSCIdate Have Now Joined Cactus Life Sciences Bringing With Them Extensive Rare Disease Expertise

Cactus Life Sciences has begun their exciting buy-and-build strategy adding key services to their portfolio

PRINCETON, NJ / ACCESSWIRE / April 24, 2024 / Cactus Life Sciences, a leading global scientific communications agency that works with blue chip pharma and biotechnology companies, announced today that they have acquired nspm and eluSCIdate, two dynamic medical communications and publications companies headquartered in Meggen, Switzerland with an office in the UK.

To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.
Integration of nspm and eluSCIdate
logo lockup

Cactus Life Sciences, headquartered in Princeton, New Jersey, was formed in 2010 and is best known for its transformational global operating models that provide best in class science, innovation, and efficiency. Founded 27 years ago, nspm brings extensive expertise in medical communications, publications, and event management, with a focus on rare diseases. Its sister company eluSCIdate was founded in 2020 and focuses on medical and scientific publications, combining extensive experience in medical writing with creative flair to deliver high-quality publications.

This collaboration signifies a major step forward in enhancing services for our biopharma clients, ensuring a comprehensive and fully integrated global approach to medical communications. And provides a significant employee footprint in US, UK, Switzerland, and Japan.

"As Cactus Life Sciences embarks on its forthcoming buy-and-build strategy, we're excited to unveil our first acquisition that shares so many of the same values as CACTUS, stated Oliver Dennis, the new Chairman of Cactus Life Sciences. "As we move forward, we seek partnerships that prioritize our people and clients alongside our strategic growth."

Rare diseases individually affect a small number of people, but collectively affect over 300 million worldwide, presenting significant challenges for patients and medical professionals. nspm's rare disease expertise addresses unmet needs for patients and society. Sabine Stotz, PhD, Managing Director, nspm, noted "This strategic alliance is a testament to the shared vision of excellence between Cactus Life Sciences, nspm and eluSCIdate. Together, our goal is to enrich the global landscape of scientific communications creating an even greater impact on healthcare professionals and the patients they treat".

Elvira Dsouza, President, Cactus Life Sciences remarked, "Cactus Life Sciences stands out for its unwavering commitment to excellence, innovation, and future readiness. With a focus on integrating cutting-edge technology, notably AI, we aim to elevate scientific content creation to contribute to a more accessible, informed, and transformative healthcare landscape".

About Cactus Life Sciences (cactuslifesciences.com): Cactus Life Sciences is a medical communication company that provides scientific strategy and content across the healthcare continuum, anywhere in the world ─ with a focus on science, innovation, and efficiency. We work alongside leading healthcare companies to establish the optimal role of medicines and encourage positive behaviors (physician and patient) that improve patient outcomes.

About nspm (www.nspm.com): nspm is a successful and dynamic medical communications company founded in 1997 with offices in Switzerland and the UK. nspm provides a complete range of medical writing, project management, and strategic medical communications solutions for the pharmaceutical and biotech industry across a range of therapeutic areas, with a focus on rare diseases. Our employees are committed to crafting high-quality, cost-effective solutions that exceed clients' expectations through scientific excellence, professionalism, and creativity.

About eluSCIdate (www.eluscidate.com): eluSCIdate is a medical writing agency founded in 2020 that specializes in scientific publications, providing support for the entire publication process. We use a wealth of experience in medical writing to deliver high-quality manuscripts, posters, and slides to our clients. At eluSCIdate, we are passionate about science and committed to providing clarity in scientific messaging. Through effective communication, we work with our clients to ensure their science stands out from the crowd.

Contact Information:

Laura Perry
VP of Strategy and Marketing
inquiries@cactuslifesciences.com
7327121005

SOURCE: Cactus Life Sciences

To view this piece of content from stats.nwe.io, please give your consent at the top of this page.

View the original press release on newswire.com.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Affordable Mini LED with Premium Design - Meet the TCL C7K Series23.5.2025 04:40:00 CEST | Press release

LONDON, UNITED KINGDOM / ACCESS Newswire / May 23, 2025 / TCL, a global leader in consumer electronics and the world's No.1 Ultra-large, Mini LED, and Google TV brand, has introduced the C7K Series, a new series of 4K 144Hz QD-Mini LED TVs available in screen sizes ranging from 50" inches to 115" inches. The C7K delivers advanced backlight control, high brightness performance and immersive audio technology at pricing that challenges conventional premium categories. The C7K Series is designed for those who demand more from their screen-whether that's sharper gaming, immersive movie nights, or simply an ultra-vivid sports match. Featuring QD-Mini LED technology and TCL's Precise Dimming Series, the C7K boasts up to 2880 dimming zones on the 115" model, offering deeper blacks, contrast and colour gamut levels comparable to OLED , while also providing higher peak brightness and a longer lifespan. HDR Premium 3000 and 144Hz Motion Clarity Visual performance is driven by HDR Premium 3000, ca

TCL Brings Premium Mini LED TV to More Homes with Amazon Brand Week Savings23.5.2025 04:40:00 CEST | Press release

LONDON, UNITED KINGDOM / ACCESS Newswire / May 23, 2025 / This Amazon Brand Week (26 th May - 1 st June), TCL invites consumers to upgrade their home entertainment with exclusive offers on its latest Mini LED TV series, the 2025 Q6C-UK series. Whether you're planning a summer of sports, immersive movie nights, or epic gaming sessions, these limited-time deals make premium TV technology more accessible than ever. With cutting-edge features and limited promotional pricing, there's never been a better time to bring a cinematic experience into your living room.t. At the heart of the 2025 Q-Series is TCL's next-generation QD-Mini LED technology , combining the best of QLED and OLED for pixel-level lighting precision. The advanced Quantum Dot Pro and Mini LED backlight system deliver stunning contrast, ultra-high peak brightness , and a wider colour gamut - bringing vivid colours and striking realism to every scene. With up to 512 dimming zones (on the 98" Q6C-UK model), viewers enjoy deeper

BioNxt Solutions Reports Formal Notice from the European Patent Office of Intention to Grant Patent23.5.2025 03:05:00 CEST | Press release

VANCOUVER, BC / ACCESS Newswire / May 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that the examining division of the European Patent Office ("EPO") has provided formal notice of the EPO‘s intention to grant BioNxt its core patent without significant changes. The Company's core patent filing was a comprehensive application for the sublingual delivery of anticancer drugs for the treatment of autoimmune neurodegenerative diseases. This patent family provides numerous proprietary product development and commercialization opportunities, including BioNxt's lead product, BNT23001, a sublingual thin-film formulation of Cladribine for the treatment of multiple sclerosis (MS). "Confirmation of the Company's flagship intellectual property asset in Europe is a major milestone for BioNxt," stated Hugh Rogers, CEO of BioNxt. "We expect the European paten

DCLI Drives Fleet Efficiencies with BlackBerry Radar Deployment Across 100,000 Chassis22.5.2025 07:56:00 CEST | Press release

Innovative Asset Monitoring Technology Selected by U.S.'s Largest Container Chassis Provider WATERLOO, ON / ACCESS Newswire / May 22, 2025 / BlackBerry Limited (NYSE:BB)(TSX:BB) today announced that Direct ChassisLink, Inc. ("DCLI"), the largest provider of container chassis to the U.S. intermodal industry, will deploy BlackBerry® Radar® across 100,000 of its DCL53 domestic 53-foot chassis. The rollout is part of a major initiative DCLI is undertaking to enhance the quality, reliability, visibility and operational efficiency of its fleet, with a view to setting a new freight industry standard for data driven decision-making. The deployment represents a deepening in the companies' technological collaboration. DCLI has utilized Radar devices on a subset of its fleet for over five years and after seeing the reliability and intelligence they provide, decided to exponentially increase the number of its chassis deployed with the solution while also recognizing Radar as a top tier supplier. W

Sauce Labs Becomes FSQS-Certified, Cementing Role as QA Leader for EMEA Finance22.5.2025 03:25:00 CEST | Press release

Accreditation reinforces Sauce Labs' position as the trusted software quality partner for Europe's most regulated financial institutions. SAN FRANCISCO, CA / ACCESS Newswire / May 22, 2025 / Sauce Labs, the leading platform for continuous quality, today announced it has achieved Financial Services Qualification System (FSQS) certification. This milestone further fuels the company's accelerating momentum as more financial services organizations across EMEA seek to modernize their digital infrastructure while meeting rigorous compliance requirements. With European institutions projected to spend over $1 trillion on digital transformation this year-and regulatory scrutiny at its highest level since GDPR-the need for trusted, compliant technology partners has never been greater. Sauce Labs' FSQS certification comes at a pivotal moment, reinforcing its role as the go-to quality assurance platform for modern financial services teams across EMEA. The FSQS certification, administered by Hellio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye